Priority Lists
Protocol Posting of
Activations
Phase II Evaluation of Intravenous Paclitaxel, Intraperitoneal Cisplatin, Intravenous Liposomal Doxorubicin and Intraperitoneal Paclitaxel in Women with Optimally-Debulked Stage III Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancer
| Study Coordinator(s) | Harriet O. Smith, M.D., Amy D. Tiersten, M.D., Sharon Wilczynski, M.D.,Ph.D. |
| Participants | Members, Surgeons, Pathologists, NCORP |
Closures
Metastasectomy and Chemotherapy for Lung Metastases from Soft Tissue Sarcoma: A Randomized Phase III Study
| Study Coordinator(s) | Laurence H. Baker, D.O. |
| Participants | Members, Medical Oncologists, Surgeons, Pathologists, NCORP |
| Closure Date | 2000-10-15 |
Evaluation of Ifosfamide/Mesna for Aggressive Meningeal Tumors (Malignant Meningioma, Hemangiopericytoma and Primary Nervous System Sarcoma), Phase II Study.
| Study Coordinator(s) | Leslie D. McAllister, M.D., Kurt A. Jaeckle, M.D., Wolfram E. Samlowski, M.D., Elisabeth J. Rushing, M.D. |
| Participants | Members, Medical Oncologists, Pathologists, NABTT, ECOG, NCORP |
| Closure Date | 2000-10-01 |
Amendments, Revisions, Memoranda
Phase III Trial of High Dose Interferon Alpha-2b versus Cisplatin, Vinblastine, DTIC Plus IL-2 and Interferon in Patients with High Risk Melanoma
| Study Coordinator(s) | Lawrence E. Flaherty, M.D., John A. Thompson, M.D., Ralph J. Tuthill, M.D., John Vetto, M.D., Vernon K. Sondak, M.D., Jeffrey A. Sosman, M.D. |
| Participants | Members, NCORP, Medical Oncologists, Surgeons, Pathologists, ECOG, COG, US INSTITUTIONS ONLY |
Evaluation of CHOP Plus Rituximab Plus Involved Field Radiotherapy for Stages I, IE, and Non-Bulky Stages II and IIE, CD20 Positive, High Risk Localized Aggressive Histologies of Non-Hodgkin’s Lymphoma, Phase II
| Study Coordinator(s) | Thomas P. Miller, M.D., B. Dino Stea, M.D.,Ph.D., Catherine P. Leith, M.D. |
| Participants | Members, Medical Oncologists, Pathologists, NCORP |
A Phase II Trial of 5-Fluorouracil Plus 776C85 in Patients with Advanced Pancreas Cancer
| Study Coordinator(s) | Mace L. Rothenberg, M.D., John S. Macdonald, M.D. |
A Randomized Comparison of Medroxyprogesterone Acetate (MPA) and Observation For Prevention of Endometrial Pathology in Postmenopausal Breast Cancer Patients Treated with Tamoxifen
| Study Coordinator(s) | Ronald K. Potkul, M.D., Caryl G. Salomon, M.D., Sharon Wilczynski, M.D.,Ph.D. |
| Participants | Members, Medical Oncologists, Radiation Oncologists, Surgeons, Pathologists, CALGB, NCORP |
A Phase II Trial of 5-fluorouracil Plus 776C85 in Patients With Advanced Resistant Colorectal Cancer
| Study Coordinator(s) | Cynthia G. Leichman, M.D., John S. Macdonald, M.D. |
| Participants | Members, NCORP |
A Randomized Phase III Trial Comparing Early High Dose Chemoradiotherapy and an Autologous Stem Cell Transplant to Conventional Dose CHOP Chemotherapy Plus Rituximab for CD20+ B Cell Lymphomas(with Possible Late Autologous Stem Cell Transplant) for Patients with Diffuse Aggressive Non-Hodgkin’s Lymphoma in the High-Intermediate and High Risk International Classification Prognostic Groups (A BMT Study)
| Study Coordinator(s) | Patrick J. Stiff, M.D., Avayporn P. Nademanee, M.D., Richard I. Fisher, M.D., Louis S. Constine, M.D., Raymond R. Tubbs, D.O., James Cook, M.D.,Ph.D. |
| Participants | Members, NCORP, Affiliates, Medical Oncologists, Radiation Oncologists, Pathologists, CALGB, ECOG, NCIC-CTG |
A Randomized Phase III Trial Comparing Early High Dose Chemotherapy and an Autologous Stem Cell Transplant to Conventional Dose ABVD Chemotherapy for Patients with Advanced Stage Poor Prognosis Hodgkin’s Disease as Defined by the International Prognostic Factors Project on Advanced Hodgkin’s Disease, Intergroup
| Study Coordinator(s) | Ellen R. Gaynor, M.D., Stephen J. Forman, M.D., Thomas M. Grogan, M.D. |
| Participants | Members, Medical Oncologists, Pathologists, ECOG, CALGB, NCORP |
A Phase II Pilot Study of Stereotactic Radiosurgery for Limited Malignant Melanoma Brain Metastases
| Study Coordinator(s) | James G. Douglas, M.D., Keith J. Stelzer, M.D.,Ph.D. |
| Participants | Members |
Docetaxel and Estramustine Versus Mitoxantrone and Prednisone for Advanced, Hormone Refractory Prostate Cancer, Phase III.
| Study Coordinator(s) | Daniel P. Petrylak, M.D., Jeffrey A. Jones, M.D., Maha H.A. Hussain, M.D., Donna L. Berry, R.N.,Ph.D. |
| Participants | UCOP, Medical Oncologists, Surgeons, CALGB, NCCTG, EPP, NCORP, Members, CTSU |
A Phase II Trial of R115777 (NSC #70818) in Patients with Advanced Colorectal Cancer.
| Study Coordinator(s) | Robert P. Whitehead, M.D., John S. Macdonald, M.D. |
| Participants | Members, NCORP, Medical Oncologists |
Intermittent Androgen Deprivation in Patients with Stage D2 Prostate Cancer, Phase III
| Study Coordinator(s) | Maha H.A. Hussain, M.D., Celestia S. Higano, M.D., Brian J. Miles, M.D., Paul H. Lange, M.D., E. David Crawford, M.D., Donna L. Berry, R.N.,Ph.D., Carol M. Moinpour, Ph.D. |
| Participants | Members, NCORP, UCOP, Affiliates, Medical Oncologists, Surgeons, Pathologists, CALGB, ECOG, EORTC, EPP, NCIC-CTG |
Other New Items
- IP - Pts Must Be Informed
- AC - Consent Must Be Amended
- CBR - No Registration Allowed until IRB Review
- RC - Formal Re-consent Required
- FBR - Full Board Review Required
- ER - Expedited Review Acceptable
- NR - No IRB Review Required